Hekmat K, Clemens R M, Mehlhorn U, Geissler H J, Kuhn-Régnier F, de Vivie E R
Department of Thoracic and Cardiovascular Surgery, University of Cologne, Germany.
Thorac Cardiovasc Surg. 1998 Dec;46(6):333-8. doi: 10.1055/s-2007-1010248.
Myocardial protection during cardiac surgery in patients with acute ischemia after failed PTCA remains a challenge. Our recent experimental work demonstrated that continuous coronary perfusion with warm beta-blocker-(Esmolol) enriched blood may be a useful alternative to current cardioplegia techniques, especially for compromised hearts. This technique was applied in our last 12 patients after failed PTCA (beta-B). The purpose of this retrospective study was to compare this alternative myocardial protection technique with our standard technique of cold crystalloid cardioplegia (CP).
Between January 1994 and January 1998 fifty-five patients (beta-B: n = 12; CP: n = 43) underwent emergency coronary artery bypass grafting within 24 hours after failed PTCA. The mean age in beta-B patients was 62+/-9 (SD) years, and 33% were female (CP: 59+/-9 years, 42% female, p = NS). In beta-B patients 67% had myocardial infarction (MI) prior to coronary angioplasty, 67% had an ejection fraction (EF) >55%, and coronary vessel involvement (VI) was 2.1+/-0.7. CP patients had the following findings: MI rate 42%, EF >55% in 84%, VI was 2.2+/-0.6; p = NS. Operation commenced within 25-980 min after failed PTCA. Beta-B patients received 2.7+/-0.8 grafts during 45+/-20 min continuous coronary perfusion with Esmolol enriched blood, whereas CP patients had 3.0+/-1.1 grafts in 42+/-17 min cross-clamp time, p = NS.
The total hospital stay was significantly (p = 0.004) shorter for beta-B patients (18+/-8 days) compared to CP patients (27+/-12 days). 30-days mortality rate was 9% in CP patients, whereas none of the beta-B patients died. Postoperative low cardiac output occurred in only one patient (8%) of the beta-B group and was treated with an intra-aortic balloon pump (IABP). Eight (19%) of the CP patients required an IABP and in five (12%) patients an additional ventricular assist device was necessary (LVAD: n = 4; RVAD: n = 1). The need for circulatory support with inotropes was significantly lower in beta-B patients. Cumulative postoperative dosage of dopamine and dobutamine was 34516+/-40400 microg/kg and 16221+/-26678 microg/kg respectively in CP patients. Beta-B patients required only 12457+/-14738 microg/kg (p = 0.02) dopamine and 5112+/-7381 microg/kg (p = 0.01) dobutamine. Perioperative myocardial infarction occurred in 53% of the CP patients and 17% of beta-B patients (p = 0.046). Total CKmax was significantly (p = 0.003) higher in CP patients (812+/-531 U/L) than in beta-B patients (457+/-265 U/L). Four CP patients (9%) had acute postoperative renal failure requiring hemofiltration, and 11 CP patients (26%) had acute postoperative pneumonia. In beta-B patients one patient (8%) suffered from postoperative pneumonia (p = NS) and no patient had renal failure (p = NS).
These clinical results appear to confirm our experimental data and suggest that continuous coronary perfusion with warm esmolol-enriched blood is superior to crystalloid cardioplegia in terms of in-hospital complications and mortality, especially for compromised hearts after failed PTCA.
经皮冠状动脉腔内血管成形术(PTCA)失败后发生急性缺血的患者,心脏手术中的心肌保护仍是一项挑战。我们最近的实验研究表明,持续冠状动脉灌注富含温血β受体阻滞剂(艾司洛尔)的血液,可能是目前心脏停搏技术的一种有用替代方法,尤其适用于功能受损的心脏。该技术应用于我们最近的12例PTCA失败后的患者(β - B组)。本回顾性研究的目的是将这种替代心肌保护技术与我们的标准冷晶体心脏停搏技术(CP)进行比较。
1994年1月至1998年1月期间,55例患者(β - B组:n = 12;CP组:n = 43)在PTCA失败后24小时内接受了急诊冠状动脉旁路移植术。β - B组患者的平均年龄为62±9(标准差)岁,33%为女性(CP组:59±9岁,42%为女性,p = 无显著性差异)。β - B组患者中67%在冠状动脉血管成形术前发生过心肌梗死(MI),67%的射血分数(EF)>55%,冠状动脉血管受累(VI)为2.1±0.7。CP组患者有以下情况:MI发生率42%,84%的EF>55%,VI为2.2±0.6;p = 无显著性差异。手术在PTCA失败后25 - 980分钟内开始。β - B组患者在45±20分钟的持续冠状动脉灌注富含艾司洛尔的血液过程中接受了2.7±0.8支移植血管,而CP组患者在42±17分钟的主动脉交叉钳夹时间内有3.0±1.1支移植血管,p = 无显著性差异。
与CP组患者(27±12天)相比,β - B组患者的总住院时间显著缩短(p = 0.004)(18±8天)。CP组患者的30天死亡率为9%,而β - B组患者无一死亡。β - B组仅1例患者(8%)术后出现低心排血量,并接受了主动脉内球囊反搏(IABP)治疗。8例(19%)CP组患者需要IABP,5例(12%)患者还需要额外的心室辅助装置(左心室辅助装置:n = 4;右心室辅助装置:n = 1)。β - B组患者对血管活性药物进行循环支持的需求显著更低。CP组患者术后多巴胺和多巴酚丁胺的累积剂量分别为34516±40400μg/kg和16221±26678μg/kg。β - B组患者仅需要12457±14738μg/kg(p = 0.02)多巴胺和5112±7381μg/kg(p = 0.01)多巴酚丁胺。围手术期心肌梗死在53%的CP组患者和17%的β - B组患者中发生(p = 0.046)。CP组患者的总肌酸激酶峰值(CKmax)显著高于β - B组患者(p = 0.003)(812±531 U/L比457±265 U/L)。4例(9%)CP组患者术后发生急性肾衰竭需要血液滤过,11例(26%)CP组患者发生急性术后肺炎。β - B组患者1例(8%)发生术后肺炎(p = 无显著性差异),无患者发生肾衰竭(p = 无显著性差异)。
这些临床结果似乎证实了我们的实验数据,并表明持续冠状动脉灌注富含温艾司洛尔的血液在住院并发症和死亡率方面优于晶体心脏停搏,尤其适用于PTCA失败后功能受损的心脏。